This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; Anthera Pharmaceuticals announcing that it has commenced screening in Europe in the Phase III non-inferiority RESULT study comparing the pancreatic enzyme replacement therapy (PERT) Sollpura to Pancreaze for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF); Protalix BioTherapeutics’ announcing new positive Phase II trial results for Protalix BioTherapeutics’ AIR DNase (alidornase alfa; PRX-110) which were presented at the 40th European Cystic Fibrosis Society Conference in Seville, Spain in June 2017; and Verona Pharma initiating a Phase II pharmacokinetic trial in the US for RPL554, the company’s a first-in-class, inhaled, long-acting, mixed phosphodiesterase (PDE) 3/4 inhibitor, following the acceptance of an Investigational New Drug application (IND) by the US FDA.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved